<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Genmab A/S and licensee GlaxoSmithKline plc are developing ofatumumab, an anti-CD20 human mAb, for the potential intravenous treatment of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo>, such as <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA) and multiple <z:mp ids='MP_0000612'>sclerosis</z:mp> (MS) </plain></SENT>
<SENT sid="1" pm="."><plain>Phase I and II clinical trials have been completed in patients with <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL), rituximab-refractory follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) and RA </plain></SENT>
<SENT sid="2" pm="."><plain>At the time of publication ofatumumab was undergoing a phase II clinical trial in patients with diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and phase III clinical trials in patients with <z:e sem="disease" ids="C0023434" disease_type="Neoplastic Process" abbrv="BCLL">B-cell CLL</z:e> (B-CLL) in which fludarabine and alemtuzumab treatments have failed and in patients with rituximab-refractory FL </plain></SENT>
<SENT sid="3" pm="."><plain>Ofatumumab was also undergoing phase II clinical trials as a combination therapy for previously untreated patients with FL in combination with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, adriamycin, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> and in combination with fludarabine and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> for the treatment of B-CLL </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, two phase III clinical trials to assess patients who have an inadequate response to <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and TNFalpha therapy were ongoing for patients with RA, and a phase II clinical trial to investigate the effects of repeated doses of ofatumumab was recruiting patients with RA from a previous trial on ofatumumab </plain></SENT>
<SENT sid="5" pm="."><plain>A phase I/II clinical trial of ofatumumab in relapsing-remitting MS was expected to commence in 2008 </plain></SENT>
</text></document>